The SITC Multiple Myeloma Expert Panel has updated the guidelines content and recommendations based on the November 30, 2021 FDA approval of daratumumab in combination with carfilzomib and dexamethasone (D-Kd) for adult patients with relapsed or refractory multiple myeloma who have received 1−3 prior lines of therapy. The approval was based on an overall response rate (ORR) of 84.8% (95% CI, 73.9% to 92.5%) with the majority of responses ongoing at 9 months in the PLEIADES trial (NCT03412565).
The updates to this guideline are found in the Monoclonal Antibodies Expert Panel Recommendations section and Multiple Myeloma Key Monoclonal Antibody Therapies Trials table on the CPG Mobile App. More information about these changes as well as the other updates that have been made to the guidelines content since the original 2020 publication in JITC can be found in the “Multiple Myeloma Guideline Updates” tile within the Multiple Myeloma guideline section of the CPG mobile app.
February 1, 2022